We regard the refresh cycle to have begun in Q2/25.
Redeye comments on Magle’s strategic pivot toward profitability, operational discipline, and sustain...
* Q4e sales SEK 45m (58m), adj. EBIT SEK 10m (19m) * We cut '26e-'27e sales and EBIT by 10% and 22-1...
Suominen Q4 comparable EBITDA of EUR 1.9m came 60% below Vara Research consensus expectations.
Suominen’s Q4 results were lower than estimated as excess nonwovens capacity still hurt volumes, lea...
Redeye comments on q.beyond’s preliminary Q4 figures, showing stronger EBITDA than expected.
Redeye comments on Gentoo Media’s preliminary Q4-results where EBITDA was above our forecast, while ...
Physitrack released preliminary Q4 2025 figures this morning, which were broadly in line with our ex...
Our estimate revisions are driven by USD/SEK movements (down almost 7% since our Q3 review) lowering...
* 27% y-o-y organic sales growth in Q4'25e * No change to financial targets expected Q4'25 results d...
Scibase has now disclosed the final outcome of its rights issue, in addition to announcing the outco...
Redeye returns with a more in-depth take on Xvivo’s Q4 report.
The Q4 report was a bit of a mixed bag, but there are some “extenuating circumstances”.
We expect CapMan’s Q4 fee business to have developed steadily from Q3 with some seasonally increased...
Kalqyl publicerar nu en sektorrapport om svenska e-handelsbolag.
* Strong orders should continue to convert into sales growth (17%) * Enedo stabilising as comps ease...
Redeye comments on Faron’s announcements of the phase I/II investigator-initiated trials BEXAR and B...
* Impairments of ~SEK 240m in Q4 * Preliminary Q4 EBIT of ~SEK -315m (vs.
* We forecast sales -27% y-o-y, driven by EEs -13% and FX -9% * Substantial market weakness, tough c...
We expect a strong positive share price reaction today of c15%, given the beat on sales, profitabili...